These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 12854090

  • 1. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A.
    J Infect Dis; 2003 Jul 15; 188(2):327-38. PubMed ID: 12854090
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.
    Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, Kiviat NB, Jansen KU, Barber H, Smith JF, Tadesse A, Giacoletti K, Smith PR, Suhr G, Johnson DA.
    Vaccine; 2004 Jul 29; 22(21-22):2943-52. PubMed ID: 15246631
    [Abstract] [Full Text] [Related]

  • 11. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
    Ault KA.
    Obstet Gynecol Surv; 2006 Jun 29; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice.
    Han JE, Kim HK, Park SA, Lee SJ, Kim HJ, Son GH, Kim YT, Cho YJ, Kim HJ, Lee NG.
    Int Immunopharmacol; 2010 Feb 29; 10(2):169-76. PubMed ID: 19874917
    [Abstract] [Full Text] [Related]

  • 14. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, Dessy F, Giannini SL, Descamps D, Dubin G.
    Vaccine; 2014 Jun 17; 32(29):3694-705. PubMed ID: 24674663
    [Abstract] [Full Text] [Related]

  • 15. Human papillomavirus vaccines.
    Breitburd F, Coursaget P.
    Semin Cancer Biol; 1999 Dec 17; 9(6):431-44. PubMed ID: 10712890
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
    Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J.
    Virology; 1998 Dec 05; 252(1):39-45. PubMed ID: 9875315
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A.
    Virology; 2006 Sep 30; 353(2):451-62. PubMed ID: 16863657
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy of human papillomavirus vaccination.
    Ault KA.
    Gynecol Oncol; 2007 Nov 30; 107(2 Suppl 1):S27-30. PubMed ID: 17938016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.